EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Real‐World Data on the Use of Follitropin Delta in a Dutch IVF Center

Pauline Boom iD, Eva C Creutzberg, Maria P H Koster, Joop S E Laven

Reproductive Medicine and Biology · 2026-01 · 25 (1)

DOI: 10.1002/rmb2.70050 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Reproductive Medicine and Biology, online erschienen am 05.06.2026. Verfasst von Pauline Boom und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology Erasmus University Medical Centre Rotterdam the Nethe…. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Research Question How does follitropin delta administered with an individualized dose based on body weight and AMH perform in daily practice, and is this comparable to results from a randomized phase III clinical trial in terms of ovarian response, pregnancy, and safety?

Design

This is a descriptive analysis of real‐world data obtained from the Erasmus University Medical Centre (EMC). Patients were treated with the dose of follitropin delta calculated according to the algorithm described in the ESTHER‐1 trial. Outcome data were restricted to the first IVF cycle in patients with a regular ovulatory cycle treated with a GnRH antagonist protocol for whom the intended day of embryo transfer was day 5.

Results

The ongoing pregnancy rate was 30.8% per started cycle, which is equivalent to the ESTHER‐1 trial. The number of oocytes retrieved (10.3 ± 5.4) was also comparable. All other ovarian response parameters were within the range that was expected on the basis of the results of the ESTHER‐1 trial.

Conclusions

The use of follitropin delta in a real‐world clinical setting results in ovarian response outcomes comparable in range to those in the follitropin delta arm of the ESTHER‐1 registration trial. No differences were observed in treatment outcomes.

Schlagwörter

Stichwörter der Autor:innen

anti‐Mullerian hormonefollitropin deltaovarian stimulation

Autor:innen und Institutionen

  • Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology Erasmus University Medical Centre Rotterdam the Netherlands.
  • InHolland University of Applied Sciences Faculty of Health, Sports and Welfare Haarlem the Netherlands.

ORCID-Profile: Pauline Boom

Zitieren

APA

Boom, P., Creutzberg, E. C., Koster, M. P. H., & Laven, J. S. E. (2026). Real‐World Data on the Use of Follitropin Delta in a Dutch IVF Center. Reproductive Medicine and Biology, 25(1). https://doi.org/10.1002/rmb2.70050

Vancouver

Boom P, Creutzberg EC, Koster MPH, Laven JSE. Real‐World Data on the Use of Follitropin Delta in a Dutch IVF Center. Reproductive Medicine and Biology. 2026;25(1). doi:10.1002/rmb2.70050

BibTeX
@article{Boom2026,
  author = {Boom, Pauline and Creutzberg, Eva C and Koster, Maria P H and Laven, Joop S E},
  title = {Real‐World Data on the Use of Follitropin Delta in a Dutch IVF Center},
  journal = {Reproductive Medicine and Biology},
  year = {2026},
  volume = {25},
  number = {1},
  doi = {10.1002/rmb2.70050}
}
Kostenlos starten →